

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **TONI IBRAHIM**
Address [REDACTED]
[REDACTED]
[REDACTED]
Telephone [REDACTED]
E-mail [REDACTED]
[REDACTED]
[REDACTED]
Nationality [REDACTED]
Place and Date of birth [REDACTED]

WORK EXPERIENCE

- Participant in a course in Cellular Biology at the Laboratory of Cellular Biology (Istituto di Anatomia Umana Normale, University of Ferrara, Italy) during the academic year 1990-1991
- Post-graduate training at S. Anna hospital, Ferrara, Italy: Medical Oncology Dept, General Surgery, Institute of Clinical Obstetrics & Gynecology, A&E, and Laboratory of the Institute of Anatomy and Histology (1996-1997)
- Various freelance and fixed-term contracts (Istituto Oncologico Romagnolo) at Pierantoni Hospital, Forlì, Italy: Medical Oncology Dept - Medical Oncologist with clinical (inpatient, Day Hospital, outpatient clinic, and home care) and research responsibilities (phase I-IV, in Good Clinical Practice) (1997-2008)
- Freelance contract with AIL (Italian Association against Leukemia, Forlì-Cesena branch), treating Oncohaematology patients (blood transfusions etc) in the Forlì province, Italy (Oct-

Dec 2001)

- Medical Director of Sanibel Srl Polyclinic, Meldola (FC), Italy, a subsidized private health facility with the National Health Service (Jul 2003-Feb 2005)
- Founder and Head of the Osteoncology Center, IRST-IRCCS (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (20 Jan 2005-09 May 2021).
- Founder and Head of Rare Tumors Center , IRST-IRCCS (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (Jan 2011-09 May 2021).
- Head of Immunotherapy, Somatic Cellular Therapy and Biobank, IRST-IRCCS (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (April 2020-09 May 2021).
- Permanent contract form Feb 2008 with IRST- IRCCS and Head of the Osteoncology and Rare Tumors Center (CDO-TR), until May 09 th 2021, which include 6 Oncologists and 7 Lab Researchers. The CDO-TR is a Center of Excellence for ISO (Italian Society of Osteoncology) criteria and member of National Network of Osteoncology and Rare Tumors and EURACAN (EUropean RARE CANcers). Head of the Unit (April 2020- May 2021): Immunotherapy, Somatic Cellular Therapy and Biobank (ITCB) which include 3 Oncologists, 5 Lab reasearchers, the Immuno-Gene Therapy Factroy include 4 biologists and 4 lab technicians, The Biobank include 3 biologists and 1 lab technician. Dr Ibrahim coordinate 32 professionals. The CDO-TR and ITCB offering mono and multidisciplinary assistance, basic and translational research and training program
- Coordinator of the multidisciplinary group of Head and Neck Cancer and Rare Tumors of The Comprehensive Cancer Care Network- AUSL Romagna/IRST- IRCCS, of Romagna, Italy. (15 Feb 2018- 09 May 2021)
- From May 10 th 2021, at IRCCS Istituto Ortopedico Rizzoli (Rizzoli Orthopedic Institute IOR), Bologna: Director of “Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit” which include 6 Oncologists, 11 Lab Researchers and 2 Study Coordinators; Coordinator of Multidisciplinary Groups and Networks in Osteoncology and Sarcomas and Coordinator of Translational Oncologic Research at IOR.
- Visiting Scientist from 07/02/12 to 07/28/12 at The Methodist Hospital Research Institute, Houston- Texas, USA , from 07/30/12 at 08/11/12 at Molecular Department, Princeton University, Princeton- New Jersey, USA and form 10/12/2014 at 10/22/2014 at the Urology department of Leiden University

Medical center, The Netherlands.

EDUCATION AND TRAINING

- Degree in Biological Sciences (BSc) with Master (MSc) in Physiology (Lebanese University of Beirut, Lebanon, 1989)
- Degree in Medicine with Honours (110/110) (University of Ferrara, Italy, 1996)
- Specialization in Medical Oncology with Honours (50/50) (University of Ferrara, Italy, 2000)
- Admitted to practice and member of the Order of Physicians in the Forli-Cesena Province, Italy (1997-present)
- Master of Science (MSc) degree in Osteoncolgy (University of Modena and Reggio Emilia, Italy, 2005)
- PhD in Experimental and Clinical Oncology (University of Modena and Reggio Emilia, Italy, 2009)
- Qualified to the management of Complex Structures of Healthcare at 9th dec 2015 at the University of Ferrara and the Emilia-Romagna Region

RESEARCH PUBLICATIONS AND EDITORIAL ACTIVITIES

Author and co-author of : over 400 scientific abstracts, 9 teaching materials, 134 scientific articles peer reviewed (H index 30 Google Scholar and 25 Scopus and web of science at 12th Feb 2021), editor of 2 books, author of 16 book chapters and 1 newspaper article relating to a national public health interest. Editor in *Frontiers in Oncology*, *Computational and Structural Biotechnology Journal*, *Materials Today and Biomedicines*. Reviewer of *Annals of Oncology*, *Cancer Letters*, *Future Oncology*, *Biomaterials*, *Tumor Biology*, *Aging*, *Biomacromolecules*, *Molecular Cancer*, *Nanomaterials*, *Therapeutics and Clinical Risk Management*, *Clinical & Experimental Metastasis*, *Int J Mol Science*, *Oncotarget*, *ACC Nano*, *Materials*, *International Journal of Cancer*, *Biomarker Insights*, *Journal of Functional Biomaterials*, *Endocrine*, *The Oncologist*, *Clinical Medicine Insights: Case Reports*, *Current Medical Research & Opinion*, *Scientific Reports*, *Cancers*, *OncoTargets and Therapy*, *Histochemistry and Cell Biology*, *Colorectal Cancer*, *Expert Opinion On Investigational Drugs*, *Journal of Functional Biomaterials*, *Medical Science Monitor*, *Clinical Medicine Insights: Endocrinology and Diabetes*, *Oncology Letters*, *Peer J*, *World Journal of Surgical Oncology and Pharmaceutics*.

European Research Council (ERC) Reviewer.

Reviewer of the National Science Center, Poland.

Registered in REPRISE (the Register of Scientific Experts set up at the

MIUR, Italian Ministry of Instruction, University and Research) for the following sections: Applied research.

Patent: designation as inventor, EP application entitled “Engineered nanovesicles and uses thereof” has been filed October 1, 2019. Application no. is EP19200824.1.

Research calls won:

- 1) Italian Ministry of Health, 2006, RFPS-2006-6-341882 (Local PI): Research and management of patients with bone metastases.
- 2) AGENZIA ITALIANA PER IL FARMACO (AIFA) 2012 (Local PI). Clinical trial: "Studio prospettico, multicentrico, di fase III, randomizzato, di non inferiorità, di confronto di acido zoledronico (ZOMETA®) somministrato ogni 12 settimane verso ogni 4 settimane nel carcinoma non a piccole cellule del polmone (NSCLC) in pazienti con metastasi ossee – Protocollo ZEN" – code FARM9I37AY2.
- 3) Italian Ministry of Health (Conto Capitale Call 2015 as PI): CC-2015-2361049 Development and Validation of innovative nanosystems for breast cancer treatment.
- 4) AGENZIA ITALIANA PER IL FARMACO (AIFA) 2016 (Local PI): Clinical Trial “Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Adrenocortical Carcinoma with high risk of recurrence (Trial ACACIA)”. Code AIFA-2016-02364512
- 5) Ministero della Salute Italiano: Bando GR-2016-02364704. Title: An in vitro and ex vivo model of biomimetic regenerative devices to treat bone metastases and soft tissue tumors: BIOBOS PROJECT. PI: Laura Mercatali (Component of the group of Dr Toni Ibrahim)
- 6) Ministero della Salute Italiano: Bando GR-2016- 02364834 (Local PI) Randomized phase II study of Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients with Advanced Soft Tissue Sarcomas: the MetropholyS trial
- 7) Ministero dell’Istruzione, Università e della Ricerca Italiano (MIUR) (Domanda n. ARS01_00769, Programma Operativo Nazionale 2018 PON) (Local PI): Nanofotonica per nuovi approcci diagnostici e terapeutici in Oncologia e Neurologia - NeON ”.
- 8) Ministero della Salute Italiano: progetto RF-2018-12368004 (Principal Investigator and coordinator of the consortium):“A theraNostic approach to reduce local recurrence of MYxofibrosarcoma (HYdRA) “
- 9) POR-FESR EMILIA ROMAGNA 2014-2020. Bando 2018 Progetti di ricerca industriale strategica rivolti agli ambiti prioritari della Strategia di Specializzazione Intelligente. Principal Investigator and coordinator of the consortium. Progetto: “Sviluppo e validazione di biomateriali medicati nanostrutturati per il trattamento e la rigenerazione del tessuto Osseo metastatico – DINAMICA”
- 10) Ministero della Salute Italiano: Bando GR-2019-12370014. Autologous ECM-composed scaffolds and zebrafish PDXs for individualized Theranostics in rare neuroendocrine neoplasms

**PERSONAL SKILLS
AND COMPETENCES**

- Until May 09 th, The Osteoncology and Rare Tumors Center (CDO-TR) includes on the staff over to Dr. Ibrahim, 6 medical oncologists and 7 Lab Researchers. Dr Ibrahim then manages human and economic resources. In particular:
 - 1) shows the number of patients treated at the CDO-TR in the following years: 2011 (1584 patients), 2012 (1753), 2013 (1993), 2014 (2405), 2015 (3139), 2016 (3149), 2017 (3085), 2018 (2964) and 2019 (3444).
 - 2) the results of the assessment of achievement of management objectives (Assistance, Research and Training) and budgets conclusion: 2011 (100%); 2012 (100%); , 2013 (97%); 2014 (99%), 2015 (100%), 2016 (100 %), 2017 (100%), 2018 (100 %) and 2019 (100 %).From April 1st 2020, head of the Unit (ITCB): Immunotherapy, Somatic Cellular Therapy and Biobank (ITCB) which include 19 professionals. The CDO-TR and ITCB offering mono and multidisciplinary assistance, basic and translational research and training program
- Organized and realized the Italian national project “multidisciplinary management of bone metastasis: Osteoncology”
- Instituted the Osteoncology Center at Pierantoni Hospital, Forlì, and IRST- IRCCS, comprising a multidisciplinary team of 22 healthcare professionals involved in patient care, research (preclinical, translational and clinical) and teaching in bone cancer disease (Jan 2005- May 2021)
- Instituted the Rare Tumors Center at IRST- IRCCS, comprising a multidisciplinary team of healthcare professionals involved in patient care, research (preclinical, translational and clinical) and teaching in Rare Tumors (Sarcomas, Neuroendocrine Tumors, Head and Neck, Skin non melanoma and Neurologic tumors) (from Jan 2011 to May 2021)
- Co-Founder, Past president (2008-2014) and currently member of the Advisory Board of the Italian Society of Osteoncology (ISO).
- Founder on 2016, of the Multidisciplinary Osteoncology School (MOS) at IRST, Meldola (Italy), with the main objective, to promoting theoretical and practical courses at IRST in mono/multidisciplinary assistance and translational research in Osteoncology.

- From 1996 to 2000 followed patients during the specialization in oncology with high dose chemotherapy and peripheral autologous stem cell transplantation. Subsequently followed these patients in oncology where he carried out his clinical activities.
- Founder member of the IMI (Italian Melanoma Intergroup)
- Honorary member of the Association for the Study of Psychology and Neuroscience, "G. M. Balzarini "
- Biology lecturer for 5th year students at a private Lebanese High School (École des Filles de la Charité) during the academic year 1989-90
- From 2007 to May 2021 at IRCCS- Istituto Romagnolo per lo Studio dei Tumori IRST Dino Amadori: Scientific Responsible of Zebrafish Facility, Principal Investigator of 41 clinical and translational research studies and Co-Responsible of Research Line 2: “ Development of Clinical and Biological (cellular and molecular) rationale for innovative multicentric clinical studies of new drugs” of the three-year program of Research of IRST IRCCS-Meldola (Italy) submitted to the Italian Ministry of Health and Member of the “Scientific Medical Advisory Board” of IRST IRCCS- Meldola (Italy)
- From May 10th 2021, at IRCCS Istituto Ortopedico Rizzoli (Rizzoli Orthopedic Institute IOR), Bologna: Director of “Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit” which include 6 Oncologists, 11 Lab Researchers and 2 Study Coordinators; Coordinator of Multidisciplinary Groups and Networks in Osteoncology and Sarcomas and Coordinator of Translational Oncologic Research at IOR.
- Member of Regional Board (Regione Emilia Romagna) of Rare Tumors
- Member of Head and Neck , Brain, Breast, Endocrine, and Soft tissue and Bone EORTC groups
- University lecturer, Master II level in Osteo-Oncology (Form III: The pathophysiology of bone and epidemiology in Osteo-Oncology), and part of the Master organizing committee (University of Modena and Reggio Emilia, Italy, 2004-2006)
- Author of the Associazione Italiana di Oncologia Medica (AIOM) guidelines: “Treatment of bone metastases, Thyroid Tumors and Neuroendocrine Neoplasms”
- PhD lecturer in Osteo-Oncology (University Campus Bio-Medico, Rome) and in Oncology, Hematology and Pathology (University of Bologna)
- Tutor for 1 PhD student in Oncology/Haematology and Pathology (Bologna University) and 2 medical trainees in Oncology (Ferrara University)
- Participated in national and international conferences as chairman, organizer, rapporteur or lecturer
- Participated as a speaker at training courses for volunteers in patient assistance programs

MOTHER TONGUE **ARABIC**

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ITALIAN, FRENCH, ENGLISH

Good
Good
Good

SOCIAL SKILLS
AND COMPETENCES

BOARD MEMBER OF A PARISH GROUP WITH THE AIM OF TRAINING AND VOLUNTEERING ACTIVITY

ORGANISATIONAL SKILLS
AND COMPETENCES

- Director of “Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit” at IRCCS Istituto Ortopedico Rizzoli (Rizzoli Orthopedic Institute IOR), Bologna: which include 6 Oncologists, 11 Lab Researchers and 2 Study Coordinators.

- Coordinator of Multidisciplinary Groups and Networks in Osteoncology and Sarcomas at IOR, Bologna

- Coordinator of Translational Oncologic Research at IOR, Bologna

- Member of the Board and Adviser for Clinical Research of the Italian Society of Osteoncology (ISO)

- Member of Regional Board of Cancer Drugs (GRFO) and Regional Board of Rare Tumors

-Reviewer of the European Research Council (ERC).

-Reviewer of the National Science Center, Poland.

-Member of the Working Group Alleanza Contro il Cancro (Sarcomas). Member of Head and Neck , Brain, Breast, Endocrine, and Soft tissue and Bone EORTC groups

AFFILIATIONS/
MEMBERSHIP

- AIOM (Associazione Italiana di Oncologia Medica)
- ASCO (American Society of Clinical Oncology)
- ESMO (European Society of Medical Oncology),
- Co-Founder, Past President, member of the Board and Adviser for Clinical Research of the Italian Society of Osteoncology (ISO)
- Member of Italian Sarcoma Group (ISG)
- Member of ENETs (European Neuroendocrine Tumor Society)
- Member of Itanet (Italian Association of Neuroendocrine Tumors)
- Member of AIOCC (Italian Head and Neck Oncologic Society)
- Member of EHNS (European Head and Neck Society)

Publications of Dr Toni Ibrahim

Scientific articles:

- 1- Maccaferri R, Ibrahim T, e al. La nutrizione parenterale totale domiciliare nel paziente oncologico: l'esperienza di Ferrara. La rivista italiana di cure palliative, Vol 2, 89-93, 2000.
- 2- Di Paolo A, Ibrahim T, e al. Relationship between plasma concentration of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusion in cancer patients. Therapeutic Drug Monitoring 24(5): 588-93, 2002.
- 3- Frassinetti GL, Ibrahim T, e al. A phase I study: Docetaxel followed by Gemcitabine in the treatment of advanced Non Small Cell Lung Cancer: A phase I study. Tumori, 88: 99-103, 2002.
- 4- Poletti P, Pinotti G, Rosati G, Luppi G, Ibrahim T, e al. "Misura" project: A retrospective survey on the use of 5-Fluorouracil in the treatment of colorectal cancer in 24 Italian clinical centers. Tumori, 88:104-109, 2002.
- 5- Di Paolo A, Danesi R, Vannozzi F, Falcone A, Mini E, Cionini L, Ibrahim T, et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther, 72:627-637, 2002a.
- 6- Ibrahim T, Fabbri M, Frassinetti GL, e al. Doxorubicin, paclitaxel, and gemcitabine: a new sequential treatment in stage IIIB-IV breast cancer: a phase I study. Journal of Chemotherapy, 15 (5): 488-494, 2003.
- 7- Toni Ibrahim, Wainer Zoli, Giovanni Luca Frassinetti e al. Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. Lung Cancer 47 (2): 261-267, 2005.
- 8- Di Paolo A, Danesi R, Ciofi L, Vannozzi F, Bocci G, Lastella M, Amatori F, Martelloni BM, Ibrahim T, e al. Improved analysis of 5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Therapeutic Drug Monitoring 27 (3): 362-368, 2005.
- 9- Ibrahim T, Serra P and Amadori D. Clinical epidemiology and specific cancer therapy of bone metastases from solid tumors. Supportive and Palliative Cancer Care Suppl 2 (3): 29- 36, 2006.
- 10- Gennari A, Amadori D, De Lena M, e al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24: 3912- 3918, 2006. *The following members of the MANTAI collaborative group also participated to the study:* National Cancer Research Institute, Genoa, Italy; Del Mastro L.; Morgagni-Pierantoni Hospital, Forli, Italy; Scarpi E., Ibrahim T., Massa I. et al.
- 11- Ibrahim T, Barbanti F, Giorgio-Marrano G e al. Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study. The Oncologist, 13:330-336, 2008.
- 12- Ibrahim T, Mercatali L, Maltoni M e al. Multidisciplinary management of bone metastases. Our experience. Minerva Chirurgica, Vol 63:230-232, 2008.
- 13- Ibrahim T, Flamini E, Fabbri, e al. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. Tumori 95,3: 291-297, 2009.

- 14- Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of Osteoblastic Bone Metastases from Prostate Cancer. *Cancer*, Mar 15;116(6):1406-18, 2010.
- 15- Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Ceconetto L, Sarti S, Pietri E, Nanni O, Amadori D. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer. *Cancer Chemother Pharmacol.* pr;65(5):871-6, 2010.
- 16- Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T. Can we consider Zoledronic acid a new antitumor agent? Recent evidence in clinical setting. *Curr Cancer Drug Targets.* *Curr Cancer Drug Targets* 1;10(1):46-54, 2010
- 17- Ibrahim T, Di Paolo A, Amatori F et al. Time-dependent pharmacokinetics of 5-Fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. *J Clin Pharmacol.* 2011 Mar 17.
- 18- Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Bone metastases detection by circulating biomarkers: OPG and RANK-L. *Int J Oncol.* Jul;39(1):255-61, 2011
- 19- Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. *Oncology* 80(3-4):225-31, 2011
- 20- Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D. Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients. *Clin Breast Cancer.* Jul 15, 2011.
- 21- Korpál M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. *Nature Medicine* Aug 7. 2011
- 22- F. Saad, J. E. Brown, C. Van Poznak, T. Ibrahim, S. M. Stemmer, A. T. Stopeck, I. J. Diel, S. Takahashi, N. Shore, D. H. Henry, C. H. Barrios, T. Facon, F. Senecal, K. Fizazi, L. Zhou, A. Daniels, P. Carrière & R. Dansey. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Annals of Oncology*, October 10, 2011
- 23- Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. *Ann Oncol.* 2012 Aug;23(8):2072-7. Epub 2012 Jan 4.
- 24- Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačičin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. E1f5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nat Cell Biol.* 2012 Oct 21. doi: 10.1038/ncb2607. [Epub ahead of print]
- 25- Daniele Santini, Francesco Bertoldo, Emanuela Dell'Aquila, Isabella Cecchini, Stefania Fregosi, Paolo Bortolussi, on behalf of the ZeTa studygroup. The Italian cross-sectional survey of the management of bone metastasis: ZeTa study. *Journal of Bone Oncology* (2012), <http://dx.doi.org/10.1016/j.jbo.2012.04.005> Appendix Other contributors: Ibrahim Toni et al.

- 26- Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48.
- 27- Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact. *Oncology.* 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.
- 28- Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Ceconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassinetti GL, Amadori D, Rocca A. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. *Heart.* 2013 Jan 28. [Epub ahead of print]
- 29- Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126(*) repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol.* 2013 Feb 10. doi: 10.1038/ncb2690. [Epub ahead of print]
- 30- Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D. Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines. *Int J Oncol.* 2013 Feb 6. doi: 10.3892/ijo.2013.1809. [Epub ahead of print]
- 31- Farolfi A; Ibrahim T; Scarpi E; Amadori D. Biology matters: the clinical impact of single-receptor discordance on breast cancer. *Annals of Oncology* 2013 24: 851-851
- 32- Ibrahim T, Farolfi A, Mercatali L, Ricci M and Amadori D. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. *Tumori*, 99: 1-9, 2013
- 33- Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *Lancet Oncol.* 2013 May 15. doi:pii: S1470-2045(13)70174-8. 10.1016/S1470-2045(13)70174-8. [Epub ahead of print]
- 34- Laura Mercatali, Marianna Ricci, Emanuela Scarpi, Patrizia Serra, Francesca Fabbri, Rossana Ricci, Chiara Liverani, Michele Zanoni, Wainer Zoli, Roberta Maltoni, Erica Gunelli, Dino Amadori 1 and Toni Ibrahim. RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study. *Int. J. Mol. Sci.* 2013, 14, 10683-10693; doi:10.3390/ijms140610683
- 35- Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial? - Authors' reply. *Lancet Oncol.* 2013 Sep;14(10):e388-90. doi:10.1016/S1470-2045(13)70295-X
- 36- TONI IBRAHIM, LAURA MERCATALI and DINO AMADORI. A new emergency in oncology: Bone metastases in breast cancer patients (Review). *ONCOLOGY LETTERS* 6: 306-310, 2013
- 37- Brian Ell, Laura Mercatali, Toni Ibrahim, Neil Campbell, Heidi Schwarzenbach, Klaus Pantel, Dino Amadori, and Yibin Kang. Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis. *Cancer Cell*, Volume 24, Issue 4, 542-556, 14 October 2013

- 38- Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. *Clin Cases Miner Bone Metab.* 2013 May;10(2):121-123.
- 39- Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, Santini D. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. *PLoS One.* 2013 Oct 28;8(10):e74402. doi: 10.1371/journal.pone.0074402.
- 40- D. Santini, G. Procopio, C. Porta, T. Ibrahim, S. Barni, C. Mazzara, A. Fontana, A. Berruti, R. Berardi, B. Vincenzi, C. Ortega, D. Ottaviani, G. Carteni, G. Lanzetta, V. Virzì, N. Silvestris, M. A. Satolli, E. Collovà, A. Russo, G. Badalamenti, S. L. Fedeli, F. M. Tanca, V. Adamo, E. Maiello, R. Sabbatini, A. Felici, G. Tonini, S. Bracarda. Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. *Plos One* 2013 Dec 30;8(12):e83026
- 41- Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D. Targeting bone metastatic cancer: Role of the mTOR pathway. *Biochim Biophys Acta.* 2014 Feb 5. pii: S0304-419X(14)00016-X. doi: 10.1016/j.bbcan.2014.01.009. [Epub ahead of print] Review.
- 42- Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 Blockade Impairs Breast Cancer Osteoclastogenic Potential in Co-Culture Systems. *Bone.* 2014 Jun 20. [Epub ahead of print]
- 43- Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y. The miRNA-23b/27b/24 Cluster Promotes Breast Cancer Lung Metastasis by Targeting Metastasis-Suppressive Gene Prosaposin. *J Biol Chem.* 2014 Jun [Epub ahead of print]
- 44- Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. *PLoS One.* 2014 Aug.
- 45- Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y. Δ Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol.* 2014 Sep 21. doi: 10.1038/ncb3040. [Epub ahead of print]
- 46- Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol.* 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36.
- 47- Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. *Onco Targets Ther.* 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014.

- 48- Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol.* 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159.
- 49- Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida F, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli M, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca F, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. *J Exp Clin Cancer Res.* 2015 Feb 5;34(1):10. [Epub ahead of print]
- 50- Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, Ceconetto L, Sarti S, Schirone A, Fedeli A, Andreis D, Pietri E, Ibrahim T, Montalto E, Amadori D. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. *Breast Cancer Res Treat.* 2015 May 27. [Epub ahead of print]
- 51- Giuseppe Bogina¹ , Gianluigi Lunardi¹ , Francesca Coati¹ , Giuseppe Zamboni¹ , Stefania Gori¹ , Laura Bortesi¹ , Marcella Marconi¹ , Paola Agnese Cassandrini¹ , Monica Turazza¹ , Laura Cortesi² , Elisabetta DeMatteis² , Guido Ficarra² , Toni Ibrahim³ , Patrizia Serra³ , Laura Medri⁴ , Sara Giraudi⁵ , Matteo Lambertini⁵ , Franca Carli⁵ , Jennifer Foglietta⁶ , Angelo Sidoni⁷ , Martina Nunzi⁸ , Corrado Ficorella⁹ , Maria Rosaria Diadema¹⁰ , Lucia Del Mastro⁵. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. *Tumori* 2015
- 52- Jean-Jacques Body , Henry G. Bone , Richard H. de Boer, Alison Stopeck , Catherine Van Poznak , Ronaldo Damiaño, Karim Fizazi, David H. Henry, Toni Ibrahim, Allan Lipton, Fred Saad, Neal Shore, Toshimi Takano, Adam J. Shaywitz, Hwei Wang , Oswaldo L. Bracco, Ada Braun, Paul J. Kostenuik. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. *European Journal of Cancer* (2015)
- 53- Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, Di Iorio V, D'Errico V, Caroli P, Monti M, Paganelli G. Feasibility and utility of re-treatment with ¹⁷⁷Lu-DOTATATE in GEP-NENs relapsed after treatment with ⁹⁰Y-DOTATOC. *Eur J Nucl Med Mol Imaging.* 2015 Jun 26.
- 54- Farolfi A, Ferrario C, Aquilina M, Ceconetto L, Tartaglia A, Ibrahim T, Serra L, Oboldi D, Nizzoli M, Rocca A. Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review. *Oncol Lett.* 2015 Aug;10(2):773-777. Epub 2015 Jun 5.
- 55- Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. *Onco Targets Ther.* 2015 Dec 3;8:3613-9. doi: 10.2147/OTT.S91971. eCollection 2015.
- 56- Daniele S, Sandro B, Salvatore I, Alfredo F, Francesco F, Domenico G, Luca M, Nicla LV, Toni I, Fausto P, Enrico V, Laura G, Davide O, Flavia L, Cinzia O, Antonio R, Giuseppe B, Elena C, Gaetano L, Giovanni M, Vincenzo A, Filippo de M, Satolli MA, Flavia C, Andrea M, Tanca FM, Raffaele A, Marco R, Sterpi M, Francesco P, Bruno V, Giuseppe T. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. *Sci Rep.* 2015 Dec 22;5:18670. doi: 10.1038/srep18670.

- 57- Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. *BMC Cancer*. 2015 Dec 22;15(1):998. doi: 10.1186/s12885-015-2038-7.
- 58- Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E. Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. *Int J Mol Sci*. 2016
- 59- Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). *Support Care Cancer*. 2016
- 60- Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Ceconetto L, Amadori D, Mercatali L. RANKL: A promising circulating marker for bone metastasis response. *Oncol Lett*. 2016 Oct;12(4):2970-2975.
- 61- Alessandro De Vita, Laura Mercatali, Federica Recine, Federica Pieri, Nada Riva, Alberto Bongiovanni, Chiara Liverani, Chiara Spadazzi, Giacomo Miserocchi, Dino Amadori, Toni Ibrahim. *OncoTargets and Therapy* 2016;9 6233–6246
- 62- Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. *Int J Mol Sci*. 2016 Nov 1;17(11). pii: E1827.
- 63- Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, Fabbri F. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. *Oncotarget*. 2016 Nov 29. doi: 10.18632/oncotarget.13682. [Epub ahead of print]
- 64- Activity of eribulin in a primary culture of well differentiated /dedifferentiated adipocytic sarcoma . Alessandro De Vita, Giacomo Miserocchi, Federica Recine, Laura Mercatali, Federica Pieri, Laura Medri, Alberto Bongiovanni, Davide Cavaliere, Chiara Liverani, Chiara Spadazzi, Dino Amadori, Toni Ibrahim. *Molecules* 2016 Dec 3;21(12). pii: E1662.
- 65- Outcome Analysis of First-Line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT. Alberto Bongiovanni; Federica Recine; Nada Riva; Flavia Foca; Chiara Liverani; Laura Mercatali; Silvia Nicolini; Federica Pieri; Dino Amadori; Toni Ibrahim. *Clinical Lung Cancer* 2016 Nov 21. pii: S1525-7304(16)30358-8. doi: 10.1016/j.clcc.2016.11.004.
- 66- Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Buggingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L. Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. *Oncotarget*. 2017 Jan 4. doi: 10.18632/oncotarget.14482.
- 67- Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, Fazio N, Delle Fave G. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. *Pancreas*. 2017 Jan 18. doi: 10.1097/MPA.0000000000000762.

- 68- Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T. Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. *Biol Open*. 2017 Feb 15;6(2):309. doi: 10.1242/bio.023911.
- 69- Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. *Onco Targets Ther*. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017.
- 70- Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. *Cancer Med*. 2017 May 25. doi: 10.1002/cam4.1028.
- 71- Laura Mercatali , Federico La Manna , Giacomo Miserocchi , Chiara Liverani, Alessandro De Vita, Chiara Spadazzi , Alberto Bongiovanni , Federica Recine , Dino Amadori , Martina Ghetti and Toni Ibrahim. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. *Int. J. Mol. Sci*. 2017, 18, 1655; doi:10.3390/ijms18081655.
- 72- Chiara Liverani, Laura Mercatali, Luca Cristofolini, Emanuele Giordano, Silvia Minardi, Giovanna Della Porta, Alessandro De Vita, Giacomo Miserocchi, Chiara Spadazzi, Ennio Tasciotti, Dino Amadori, Toni Ibrahim. Investigating the Mechanobiology of Cancer Cell–ECM Interaction Through Collagen-Based 3D Scaffolds. *Cellular and Molecular Bioengineering*. June 2017, Volume 10, Issue 3, pp 223–234. <https://doi.org/10.1007/s12195-017-0483-x>
- 73- Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. *J Vis Exp*. 2017 Sep 13;(127).
- 74- Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. *J Transl Med*. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review.
- 75- Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T. Primary leiomyosarcoma of the bone: a case report and a review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(45):e8545. doi: 10.1097/MD.0000000000008545.
- 76- Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(46):e8567. doi: 10.1097/MD.0000000000008567.
- 77- De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T. Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. *Int J Mol Sci*. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

78- Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. *Pancreatology*. 2018 Jan 12. pii: S1424-3903(18)30006-1. doi: 10.1016/j.pan.2018.01.005.

79- De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. *Ther Adv Med Oncol*. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.

80- Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, de Braud F, Mazzaferro V, Pastorino U, Seregini E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Maria BP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconicini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Mar 20. pii: ERC-17-0489. doi: 10.1530/ERC-17-0489. [Epub ahead of print]

81- Pusceddu S, Vernieri C, Di Maio M, Marconicini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davi MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*. 2018 Apr 12. pii: S0016-5085(18)30443-8. doi: 10.1053/j.gastro.2018.04.010. [Epub ahead of print]

82- De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T. Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. *J Vis Exp*. 2018 Apr 11;(134). doi: 10.3791/56767.

83- Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D. Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers. *J Vis Exp*. 2018 Jun 11;(136). doi: 10.3791/57113.

84- Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T. Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. *Cells*. 2018 Oct 25;7(11). pii: E186. doi: 10.3390/cells7110186.

85- Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. *Endocr Connect*. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478.

86 Chiara Liverani, Alberto Bongiovanni, Laura Mercatali, Flavia Foca, Federica Pieri, Alessandro De Vita, Chiara Spadazzi, Giacomo Miserocchi, Federica Recine, Nada Riva, Silvia Nicolini, Stefano Severi, Giovanni Martinelli, and Toni Ibrahim. Grading of Neuroendocrine Carcinomas:

Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. *Disease Markers*, 2018 Dec 2;2018:6878409.

87- Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T. Ten-year experience of the multidisciplinary Osteoncology Center. *Support Care Cancer*. 2019 Jan 16.

88- Grisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airoidi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. *PLoS One*. 2019 Mar 20;14(3):e0213934. doi: 10.1371/journal.pone.0213934. eCollection 2019.

89- Spadazzi C, Recine F, Mercatali L, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Fausti V, Ibrahim T. mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model. *J Bone Oncol*. 2019 Feb 27;16:100227. doi: 10.1016/j.jbo.2019.100227. eCollection 2019 Jun.

90- Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. *Eur J Cancer*. 2019 Jun 1. pii: S0959-8049(19)30297-7.

91- Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. *Eur J Cancer*. 2019 Jul 9;118:35-40.

92- Bongiovanni A, Recine F, Fausti V, Rossi B, Mercatali L, Liverani C, De Vita A, Gurrieri L, De Bonis S, Miserocchi G, Spadazzi C, Calpona S, Riva N, Cocchi C, Ibrahim T. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: an evidence-based review. *Int J Clin Pract*. 2019 Aug 13:e13404.

93- Bellia RB, Feliciani G, Del Duca M, Monti M, Turri V, Sarnelli A, Romeo R, Kelson I, Keisari Y, Popovtzer A, Ibrahim T, Paganelli G, Stanganelli I. Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma (cSCC) treated with Diffusing alpha emitters Radiation Therapy (DaRT): a case report. *J Contemporary Brachytherapy*, 2019 Oct;11(5):449-457

94- Liverani C, De Vita A, Minardi S, Kang Y, Mercatali L, Amadori D, Bongiovanni A, La Manna F, Ibrahim T*, Tasciotti E*. *contributed equally. A biomimetic 3D model of hypoxia-driven cancer progression. *Sci Rep*. 2019 Aug 22;9(1):12263.

95- Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D; ItaNet. Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor. *J Clin Endocrinol Metab*. 2019 Sep 23. pii: dgz035. doi: 10.1210/clinem/dgz035.

- 96- Bongiovanni A, Liverani C, Recine F, Mercatali L, Severi S, Ibrahim T. Comment on paper by Lemelin et al.: Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: The LyREMeNET study. *Neuroendocrinology*. 2019 Nov 5.
- 97- Recine F, Bongiovanni A, Foca F, Mercatali L, Fausti V, Calpona S, Riva N, De Vita A, Liverani C, Spadazzi C, Misericocchi G, Di Menna G, Gurrieri L, Cocchi C, Debonis SA, Vespignani R, Ibrahim T. Bone Health Management in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life" Experience (BOHEME Study). *J Clin Med*. 2019 Nov 6;8(11)
- 98- Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni S, Gennatas S, Jones RL, Hindi N, Martin-Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, Gronchi A, Stacchiotti S, Santini D, Tonini G, Palassini E, Vincenzi B. Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. *ESMO Open*. 2020 Jan;5(1). pii: e000604.
- 99- Vittorio Fusco, Daniele Santini, Giuseppina Campisi, Francesco Bertoldo, Gaetano Lanzetta, Toni Ibrahim, Oscar Bertetto, Gianmauro Numico, Alfredo Addeo, Alfredo Berruti, Giordana Bettini, Giorgia Saia, and Alberto Bedogni. Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. *JCO Oncology Practice, JCO Oncol Pract*. 2020 Jan 24;JOP1900645.
- 100- Cortesi M, Liverani C, Mercatali L, Ibrahim T, Giordano E. Computational models to explore the complexity of the epithelial to mesenchymal transition in cancer. *Wiley Interdiscip Rev Syst Biol Med*. 2020 Mar 24:e1488.
- 101- Santini D, Berruti A, Di Maio M, Procopio G, Bracarda S, Ibrahim T, Bertoldo F. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. *ESMO Open*. 2020 Mar;5(2). pii: e000652
- 102- Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, Spadazzi C, Misericocchi G, Cocchi C, Di Menna G, De Vita A, Severi S, Nicolini S, Ibrahim T. Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis. *Front Oncol*. 2020 Apr 7;10:414.
- 103- Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, Guercio M, Milano GM, Tamborini E, Busico A, Dagrada G, Garofalo C, Caruso C, Brunello A, Pignochino Y, Berrino E, Grignani G, Scotlandi K, Parra A, Hattinger CM, Ibrahim T, Mercatali L, De Vita A, Carriero MV, Pallocca M, Loria R, Covelto R, Sbaraglia M, Dei Tos AP, Falcioni R, Maestro R. Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. *Front Oncol*. 2020 Apr 15;10:489
- 104- Giuseppe Lamberti, Maria Pia Brizzi, Sara Pusceddu, Fabio Gelsomino, Giovanni Di Meglio, Francesco Massari, Giuseppe Badalamenti, Ferdinando Riccardi, Toni Ibrahim, Chiara Ciccicarese, Sebastiano Buti, Carlo Carnaghi, Natalie Prinzi, Francesco Panzuto and Davide Campana. Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. *J Clin Medicine J. Clin. Med*. 2020, 9, 1351
- 105- Comment on 'Reorganisation of medical oncology departments during the novel Coronavirus disease-19 pandemic: a nationwide Italian survey' by Alice Indini et al. Bongiovanni A, Mercatali L, Fausti V, Ibrahim T. *Eur J Cancer*. 2020 May 16.

- 106- Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. *Eur J Nucl Med Mol Imaging*. 2020 May 29.
- 107- Indraccolo S, De Salvo GL, Verza M, Caccese M, Esposito G, Piga I, Del Bianco P, Pizzi M, Gardiman MP, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Zagonel V, Lombardi G. Phosphorylated Acetyl-CoA Carboxylase is associated with clinical benefit with Regorafenib in relapsed glioblastoma: REGOMA Trial Biomarker Analysis. *Clin Cancer Res*. 2020 Jun 9: Clin Cancer Res.4055.2019.
- 108- Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. *Front Oncol*. 2020 May 27;10:831.
- 109- Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dehecchi MC, Prandini P, Gambari R, Scapoli C, Di Gennaro G, Caccese M, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Lippi G, Delledonne M, Zagonel V, Cabrini G. A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib. *Neuro Oncol*. 2020 Jul 14:noaa156.
- 110- Rossi R, Serra P, Suzzi M, Guerra D, Bilotta S, Ricci M, Pallotti MC, Ibrahim T, Frassinetti GL, Zavoiu V, Nanni C, Altini M, Maltoni M. The challenge for nutritional care in a cancer center: The need for integration between clinical nutritionist, oncologist, and palliative care physician. *Curr Probl Cancer*. 2020 Jul 5:100618.
- 111- Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. *BMJ Open*. 2020 Jul 19;10(7):e034393.
- 112- Cortesi M, Liverani C, Mercatali L, Ibrahim T, Giordano E. An in-silico study of cancer cell survival and spatial distribution within a 3D microenvironment. *Sci Rep*. 2020 Jul 31;10(1):12976.
- 113- Grosso F, D'Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E, Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D'Incalci M, Grignani G. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US Study) from the Italian Sarcoma Group. *Cancer*. Nov 2020.
- 114- Laranga R, Duchi S, Ibrahim T, Guerrieri AN, Donati DM, Lucarelli E. Trends in Bone Metastasis Modeling. *Cancers (Basel)*. 2020 Aug 17;12(8):E2315.
- 115- Giani C, Valerio L, Bongiovanni A, Durante C, Grani G, Ibrahim T, Mariotti S, Massa M, Pani F, Pellegriti G, Porcelli T, Salvatore D, Tavarelli M, Torlontano M, Locati L, Molinaro E, Elisei R. Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. *Thyroid*. 2020 Sep 10.
- 116- Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, Martín-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C. CAR T cells targeting options in the fight against multiple myeloma. *Panminerva Med*. 2020 Sep 21.

- 117- Cafaro A, Bongiovanni A, Di Iorio V, Oboldi D, Masini C, Ibrahim T. Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. *Front Oncol.* 2020 Aug 18;10:1478.
- 118- Marilisa Cortesi, Chiara Liverani, Laura Mercatali, Toni Ibrahim, Emanuele Giordano. Computational models to explore the complexity of the epithelial to mesenchymal transition in cancer. *WIREs Syst Biol Med.* 2020;12:e1488.
- 119- Giovanni Briigliadori, Giulia Goffredo, Daniela Bartolini, Luigino Tosatto, Lorena Gurrieri, Laura Mercatali and Toni Ibrahim. Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma. *Front Oncol.* 2020 Oct 20;10:533000
- 120- Alessandro De Vita, Alberto Bongiovanni, Jean-Yves Blay and Toni Ibrahim. Editorial: New Insights Into the Landscape of Rare Tumors: Translational and Clinical Research Perspective. *Front Oncol.* 2020 Oct 29;10:593785
- 121- Bongiovanni A, Liverani C, Foca F, Fausti V, Di Menna G, Mercatali L, De Vita A, Riva N, Calpona S, Miserocchi G, Spadazzi C, Cocchi C, Ibrahim T. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: a "Real World" data analysis. *Neuroendocrinology.* 2020 Nov 20.
- 122- Spadazzi C, Mercatali L, Esposito M, Wei Y, Liverani C, De Vita A, Miserocchi G, Carretta E, Zanoni M, Cocchi C, Bongiovanni A, Recine F, Kang Y, Ibrahim T. Trefoil Factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis. *Bone.* 2020 Nov 26:115775.
- 123- Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kaltsas G, Bertani E, Sauvanet A, Segelov E, Caplin M, Coppa J, Armstrong T, Weickert MO, Butturini G, Staettner S, Boesch F, Cives M, Moulton CA, He J, Selberherr A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Almeamar H, Frilling A, Viglia E, Wilson C, Muffatti F, Srirajaskanthan R, Invernizzi P, Lania A, Kwon W, Ewald J, Rinzivillo M, Nessi C, Smid LM, Gardini A, Tsoli M, Picardi EE, Hentic O, Croagh D, Toumpanakis C, Citterio D, Ramsey E, Mosterman B, Regi P, Gasteiger S, Rossi RE, Smiroldo V, Jang JY, Falconi M. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤ 2 cm: Study Protocol for a Prospective Observational Study. *Front Med (Lausanne)* 2020 Dec 23;7:598438.
- 124- Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. *Endocr Pathol.* 2021 Jan 6.
- 125- Pasini A, Lovecchio J, Cortesi M, Liverani C, Spadazzi C, Mercatali L, Ibrahim T, Giordano E. Perfusion Flow Enhances Viability and Migratory Phenotype in 3D-Cultured Breast Cancer Cells. *Ann Biomed Eng.* 2021 Feb 4. doi: 10.1007/s10439-021-02727-w.
- 126- Bongiovanni A, Vagheggini A, Fausti V, Mercatali L, Calpona S, Di Menna G, Miserocchi G, Ibrahim T. Induction Chemotherapy plus Concomitant Chemoradiotherapy in Nasopharyngeal Carcinoma: an Updated Network Meta-Analysis. *Crit Rev Oncol Hematol.* 2021 Feb 11:103244.
- 127- Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli

G. Combined use of ¹⁷⁷Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2021 Feb 18.

128- Alberto Bongiovanni , Flavia Foca, Manuela Fantini , Maria Rosachiaro Forcignanò , Fabrizio Artioli , Rossana Berardi⁶ , Enrico Campadelli , Giuseppe Procopio , Francesco Silvestris , Nada Riva , Lorena Gurrieri , Silvia Angela Debonis , Giandomenico Di Menna , Valentina Fausti , Federica Recine , Roberto Vespignani, Toni Ibrahim. First prospective data on breast cancer patients from the multicentre Italian bone metastasis database. *Scientific Reports* 2021, 11:4329.

129- Alessandra Santangelo, Marzia Rossato, Giuseppe Lombardi, Salvatore Benfatto, Denise Lavezzari, Gian Luca De Salvo, Stefano Indraccolo, Maria Cristina Dehecchi, Paola Prandini, Roberto Gambari, Chiara Scapoli, Gianfranco Di Gennaro, Mario Caccese, Marica Eoli, Roberta Rudà, Alba Ariela Brandes, Toni Ibrahim, Simona Rizzato, Ivan Lolli, Giuseppe Lippi, Massimo Delledonne, Vittorina Zagonel, and Giulio Cabrini. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. *Neuro-Oncology* 23(2), 264–276, 2021.

130- De Vita A, Liverani C, Molinaro R, Martinez JO, Hartman KA, Spadazzi C, Miserochi G, Taraballi F, Evangelopoulos M, Pieri F, Bongiovanni A, Mercatali L, Tasciotti E, Ibrahim T. Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. *Sci Rep*. 2021 Mar 3;11(1):5107.

131- Emanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, Angela Buonadonna, Antonella Romanini, Giuseppe Badalamenti, Virginia Ferraresi, Bruno Vincenzi, Alessandro Comandone, Antonio Pizzolorusso, Antonella Brunello, Fabio Gelsomino, Tommaso De Pas, Toni Ibrahim, Federica Grosso, Francesca Zanelli, Maria Abbondanza Pantaleo, Laura Milesi, Libero Ciuffreda, Vittorio Ferrari, Emanuela Marchesi, Irene Quattrini, Alberto Righi, Elisabetta Setola, Elisa Carretta, Piero Picci and Stefano Ferrari. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, multicenter Study of the Italian Sarcoma Group. *Cancers* 2021, 13, 1053

132- Miserochi G, Cocchi C, De Vita A, Liverani C, Spadazzi C, Calpona S, Di Menna G, Bassi M, Meccariello G, De Luca G, Campobassi A, Maddalena Tumedei M, Bongiovanni A, Fausti V, Cotelli F, Ibrahim T, Mercatali L. Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas. *Cancer Biol Med*. 2021 Mar 27; j.issn.2095-3941.2020.0482

133- Lee NY, Ferris RL, Psyrris A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E. Ibrahim Toni as collaborator PI in supplementary. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol*. 2021 Apr;22(4):450-462.

134- Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). *J Clin Oncol*. 2021 May 4;JCO2003368.

Books

- 1-Amadori D, Castoldi GL, Fabbri M, Ibrahim T, Mannella P, Rigolin GM, Scutellari PN (Editori). *Metastasi Ossee*, Ed. Medical Communications, 2003.
- 2-Amadori D, Fabbri M, Ibrahim T, Salvagni S, Mugolino A, Cascinu S. *Fisiopatologia e biologia delle metastasi ossee*. In *Osteo-oncologia, un approccio multidisciplinare*. Ed. Excerpta Medica 2003, p 1-28.
- 3-Amadori D, Ibrahim T, Fabbri M. *Storia naturale ed epidemiologia*. In *Osteo-oncologia, un approccio multidisciplinare*. Ed. Excerpta Medica 2003, p 29-42.
- 4-Amadori D, Ibrahim T, Fabbri M. *Clinica e complicanze delle metastasi ossee*. In *Osteo-oncologia, un approccio multidisciplinare*. Ed. Excerpta Medica 2003, p 59-70.
- 5-Amadori D, Ibrahim T, Fabbri M. *Terapia medica antitumorale*. In *Osteo-oncologia, un approccio multidisciplinare*. Ed. Excerpta Medica 2003, p 71-72.
- 6- Ibrahim T, Maltoni M, Amadori D. *Metastasi ossee: approccio multidisciplinare*. In *Libro italiano di cure palliative*. Ed. Poletto 2007, p 116- 119.
- 7- Amadori D, Cascinu S, Conte PF, Ibrahim T. *Osteoncology Textbook*. Ed. Poletto, 2010.
- 8- Bertoldo F, Flamini E, Santini Daniele and Ibrahim T. *Physiopathology of bone metastases*. In Amadori D, Cascinu S, Conte PF , Ibrahim T. *Osteoncology Textbook*. Ed. Poletto, 2010.
- 10- Ibrahim T et al. *Clinical manifestation*. In Amadori D, Cascinu S, Conte PF, Ibrahim T. *Osteoncology Textbook*. Ed. Poletto, 2010
- 11- Guarneri V, Bertolini F, Cascinu S, Ibrahim T. *Pharmacological Treatment*. In Amadori D, Cascinu S, Conte PF, Ibrahim T. *Osteoncology Textbook*. Ed. Poletto, 2010
- 12- Sabbatini R, Cascinu S, Ferrari A, Ibrahim T et al. *Bone metastases of unknown origin*. In Amadori D, Cascinu S, Conte PF, Ibrahim T . *Osteoncology Textbook*. Ed. Poletto, 2010
- 13- Nanni O, Bucchi L, Serra P, Flamini E, Scarpi E and Ibrahim T. *Research in osteoncology*. In Amadori D, Cascinu, S, Conte PF, Ibrahim T. *Osteoncology Textbook*. Ed. Poletto, 2010
- 14- Ibrahim T et al. *Organizational models*. In Amadori D, Cascinu S, Conte PF, Ibrahim T. *Osteoncology Textbook*. Ed. Poletto, 2010 .
- 15- *Libro Bianco. Interventi urgenti per la tutela della salute della donna con diagnosi di tumore al seno: prevenzione delle fratture indotte dalle terapie anti-ormonali*. Prisco Piscitelli | Luigi Cataliotti | Toni Ibrahim | Lucio Luzzato | Raffaella Michieli | Paolo Veronesi | Veronica Zuber | Maria Luisa Brandi. 2012

